| ||||||||||||||
|
|
|||||||||||||



*Professor of Laboratory Medicine and Psychiatry. Departments of Laboratory Medicine, Anesthesiology, Pharmacology, and Psychiatry, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510
Associate Professor of Anesthesiology. Departments of Laboratory Medicine, Anesthesiology, Pharmacology, and Psychiatry, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510
Assistant Professor of Psychiatry. Departments of Laboratory Medicine, Anesthesiology, Pharmacology, and Psychiatry, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510
Associate in Research, Department of Psychiatry. Departments of Laboratory Medicine, Anesthesiology, Pharmacology, and Psychiatry, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510
||Professor of Psychiatry and Pharmacology. Departments of Laboratory Medicine, Anesthesiology, Pharmacology, and Psychiatry, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510
Abstract
Cocaine was stable (93.6 ± 5.0 (SD) % remaining after 120 minutes) when incubated in plasma from six patients with histories of succinylcholine sensitivity and low dibucaine numbers (phenotype A), but was rapidly hydrolyzed (40.6 ± 6.6% remaining after 120 minutes) when incubated in plasma obtained from normal subjects (phenotype U). Intermediate decay (69.4 ± 9.0% remaining) occurred in three heterozygous offspring of the succinylcholinesensitive patients. Since serum cholinesterase has recently been implicated in the human metabolism of cocaine, patients who are homozygous for the atypical enzyme may be at greater risk for a toxic reaction when administered this drug. We recommend caution in using cocaine for topical anesthesia in patients with histories of succinylcholine sensitivity or low dibucaine numbers.
Key Words: ANESTHETICS, Local: cocaine BIOTRANSFORMATION (DRUG): cocaine ENZYMES: pseudocholines-terase
This article has been cited by other articles:
![]() |
S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Kuczkowski The cocaine abusing parturient: a review of anesthetic considerations: [L'abus de cocaine chez les parturientes : une revue des aspects anesthesiques] Can J Anesth, February 1, 2004; 51(2): 145 - 154. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Xie, C. V. Altamirano, C. F. Bartels, R. J. Speirs, J. R. Cashman, and O. Lockridge An Improved Cocaine Hydrolase: The A328Y Mutant of Human Butyrylcholinesterase is 4-fold More Efficient Mol. Pharmacol., January 1, 1999; 55(1): 83 - 91. [Abstract] [Full Text] |
||||
![]() |
M. M. Knuepfer and Q. Gan Role of cholinergic receptors and cholinesterase activity in hemodynamic responses to cocaine in conscious rats Am J Physiol Regulatory Integrative Comp Physiol, January 1, 1999; 276(1): R103 - R112. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Konkol, L. J. Murphey, D. M. Ferriero, D. A. Dempsey, and G. D. Olsen Cocaine Metabolites in the Neonate: Potential for Toxicity J Child Neurol, July 1, 1994; 9(3): 242 - 248. [Abstract] [PDF] |
||||
|